| pubmed-article:1975342 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1975342 | lifeskim:mentions | umls-concept:C0024623 | lld:lifeskim |
| pubmed-article:1975342 | lifeskim:mentions | umls-concept:C0596244 | lld:lifeskim |
| pubmed-article:1975342 | lifeskim:mentions | umls-concept:C0243076 | lld:lifeskim |
| pubmed-article:1975342 | pubmed:issue | 8711 | lld:pubmed |
| pubmed-article:1975342 | pubmed:dateCreated | 1990-10-3 | lld:pubmed |
| pubmed-article:1975342 | pubmed:abstractText | The relation between use of histamine-2-receptor (H2-receptor) antagonists and gastric cancer risk was investigated in a case-control study in northern Italy. 563 patients with newly diagnosed, histologically confirmed gastric cancer were compared with 1501 controls who did not have neoplastic or gastrointestinal disorders. 36 (6.3%) cases and 59 (3.3%) controls had used H2-receptor antagonists (cimetidine or ranitidine). The relative risk (RR) for ever-use was 1.8 (95% confidence intervals [CI] 1.2, 2.7). The increased risk was restricted to patients who had started treatment with H2-receptor antagonists within 5 years of the diagnosis of stomach cancer (RR 3.1; 95% CI 1.8, 5.3). For first use of H2-receptor antagonists 5-9 years previously the RR was 1.5 (95% CI 0.7, 3.3), and for first use 10 or more years previously RR was 0.2 (95% CI 0.03, 0.8). Although the incidence of gastric cancer was raised for the first few years after the start of treatment with H2-receptor antagonists, this may reflect misdiagnosis of some early gastric cancers. The findings are against long-term persistence of an excess risk of gastric cancer in association with use of H2-receptor antagonists. | lld:pubmed |
| pubmed-article:1975342 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1975342 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1975342 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:1975342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1975342 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1975342 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:1975342 | pubmed:issn | 0140-6736 | lld:pubmed |
| pubmed-article:1975342 | pubmed:author | pubmed-author:NegriEE | lld:pubmed |
| pubmed-article:1975342 | pubmed:author | pubmed-author:La VecchiaCC | lld:pubmed |
| pubmed-article:1975342 | pubmed:author | pubmed-author:FranceschiSS | lld:pubmed |
| pubmed-article:1975342 | pubmed:author | pubmed-author:D'AvanzoBB | lld:pubmed |
| pubmed-article:1975342 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1975342 | pubmed:day | 11 | lld:pubmed |
| pubmed-article:1975342 | pubmed:volume | 336 | lld:pubmed |
| pubmed-article:1975342 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1975342 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1975342 | pubmed:pagination | 355-7 | lld:pubmed |
| pubmed-article:1975342 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1975342 | pubmed:meshHeading | pubmed-meshheading:1975342-... | lld:pubmed |
| pubmed-article:1975342 | pubmed:meshHeading | pubmed-meshheading:1975342-... | lld:pubmed |
| pubmed-article:1975342 | pubmed:meshHeading | pubmed-meshheading:1975342-... | lld:pubmed |
| pubmed-article:1975342 | pubmed:meshHeading | pubmed-meshheading:1975342-... | lld:pubmed |
| pubmed-article:1975342 | pubmed:meshHeading | pubmed-meshheading:1975342-... | lld:pubmed |
| pubmed-article:1975342 | pubmed:meshHeading | pubmed-meshheading:1975342-... | lld:pubmed |
| pubmed-article:1975342 | pubmed:meshHeading | pubmed-meshheading:1975342-... | lld:pubmed |
| pubmed-article:1975342 | pubmed:meshHeading | pubmed-meshheading:1975342-... | lld:pubmed |
| pubmed-article:1975342 | pubmed:meshHeading | pubmed-meshheading:1975342-... | lld:pubmed |
| pubmed-article:1975342 | pubmed:meshHeading | pubmed-meshheading:1975342-... | lld:pubmed |
| pubmed-article:1975342 | pubmed:meshHeading | pubmed-meshheading:1975342-... | lld:pubmed |
| pubmed-article:1975342 | pubmed:meshHeading | pubmed-meshheading:1975342-... | lld:pubmed |
| pubmed-article:1975342 | pubmed:meshHeading | pubmed-meshheading:1975342-... | lld:pubmed |
| pubmed-article:1975342 | pubmed:meshHeading | pubmed-meshheading:1975342-... | lld:pubmed |
| pubmed-article:1975342 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:1975342 | pubmed:articleTitle | Histamine-2-receptor antagonists and gastric cancer risk. | lld:pubmed |
| pubmed-article:1975342 | pubmed:affiliation | Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy. | lld:pubmed |
| pubmed-article:1975342 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1975342 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1975342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1975342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1975342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1975342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1975342 | lld:pubmed |
